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Introduction: Recent studies in septic patients showed that adverse effects of hydroxyethyl starches (HESs) possibly
outweigh their benefits in severely impaired physiological haemostasis. It remains unclear whether this also applies
to patient populations that are less vulnerable. In this meta-analysis, we evaluated the impact of various HES
generations on safety and efficacy endpoints in patients undergoing cardiac surgery.
Methods: We searched the PubMed, Embase and Cochrane Central Register of Controlled Trials databases for
randomised controlled trials (RCTs) in the English or German language comparing the use of HES to any other
colloid or crystalloid during open heart surgery.
Results: Blood loss and transfusion requirements were higher for older starches with mean molecular weights more
than 200 kDa compared to other volume substitutes. In contrast, this effect was not observed with latest-generation
tetrastarches (130/0.4), which performed even better when compared to albumin (blood loss of tetrastarch versus
albumin: standardised mean difference (SMD), −0.34; 95% CI, −0.63, −0.05; P = 0.02; versus gelatin: SMD, −0.06; 95%
CI, −0.20, 0.08; P = 0.39; versus crystalloids: SMD, −0.05; 95% CI, −0.20, 0.10; P = 0.54). Similar results were found for
transfusion needs. Lengths of stay in the intensive care unit or hospital were significantly shorter with tetrastarches
compared to gelatin (intensive care unit: SMD, −0.10; 95% CI, −0.15, −0.05; P = 0.0002) and crystalloids (hospital: SMD,
−0.52; 95% CI, −0.90, −0.14; P = 0.007).
Conclusions: In this meta-analysis of RCTs, we could not identify safety issues with tetrastarches compared with other
colloid or crystalloid solutions in terms of blood loss, transfusion requirements or hospital length of stay in patients
undergoing cardiac surgery. The safety data on coagulation with older starches raise some issues that need to be
addressed in future trials.Introduction
Hydroxyethyl starches (HESs) have been used as standard
solutions for volume replacement therapy for decades.
Molecular weight and molar substitution have continu-
ously been adapted to minimise adverse effects such as
impairment of blood coagulation or renal function [1].
In 2013, in three reviews and/or meta-analyses, au-
thors have evaluated the effect of HES in different surgi-
cal settings. In the first [2], the authors analysed the
safety of tetrastarches for mortality, renal function and
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unless otherwise stated.surgical patient populations and found no adverse ef-
fects. In the second, the authors specifically evaluated
renal safety for cardiac and non-cardiac surgical patients
and found no adverse effects of HES compared to other
fluids [3]. In the third one [4], the authors also did not
identify any differences in the incidence of death or
acute kidney injury (AKI) in surgical patients. Neverthe-
less, analysis of a more homogeneous patient population
might provide more detailed insights and improve the
sensitivity of such analyses. Especially surgical patients
with relatively high perioperative blood loss, such as in
cardiovascular surgery, might reveal additional safety
information.
Shi et al. [5] analysed the use of HES in cardiovascular
surgery. However, their analysis had two major limitations.
First, it contained trials conducted by Boldt et al. which
later were retracted [6]. Second, it included studies thathis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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HES. In another analysis, Navickis et al. [8] followed a
similar strategy, but did not distinguish between different
generations of HES.
In the present meta-analysis, we reevaluate the use of
HES in cardiac surgery, separately analysing potential
negative effects of different generations. Cardiac surgery
seems to be an ideal setting for safety evaluation due to
the high need for volume replacement that should best
reveal adverse effects.
Methods
We searched various databases for randomised con-
trolled clinical trials in open heart surgery in the English
or German language in which researchers compared
HES to any other fluid. Trials comparing HES to fresh
frozen plasma (FFP) were excluded, as FFPs are no lon-
ger recommended. There was no time restriction, and all
stages of publication were eligible. The manuscript was
prepared according to the preferred reporting items for
systematic reviews and meta-analyses (PRISMA) state-
ment [9]. Because the meta-analysis was based on pub-
lished study data, approval by an ethics committee was
waived. As well, no patient consent was needed.
Literature search
Studies were identified by searching the PubMed (1946
to July 2013), Embase (1974 to July 2013) and Cochrane
Central Register of Controlled Trials (1993 to July 2013)
databases. Our search strategy can be found in Additional
file 1. Any systematic reviews were checked for further
suitable publications.
Study selection
We removed duplicates from all hits, and two independ-
ent reviewers identified studies meeting the eligibility
criteria based on the title and/or abstract. Any disagree-
ments were resolved by consulting the full text of the
article, discussion between the reviewers or consultation
with a third reviewer.
Data acquisition
All data were collected on predesigned data extraction
sheets by two experienced reviewers. In cases of any dis-
crepancies, a third reviewer was consulted. The safety,
efficacy and HES data listed below were extracted from
the included publications.
1. Safety:
a. Volume of total blood loss within 24 hours after
surgery
b. Frequency of blood transfusions within 24 hours
after surgery
c. Frequency of reoperationsd. Frequency of AKI during hospitalisation
e. In-hospital mortality
f. Length of stay in intensive care unit (ICU)
g. Length of stay in hospital2. Efficacy: combined volume of colloids and crystalloids3. HESs were classified according to their molar substitution:
a. Tetrastarch 0.4 (molecular weight (MW), 130 kDa),
b. Pentastarch 0.45 (MW, 264 kDa),
c. Pentastarch 0.5 (MW, 120, 200 or 250 kDa),
d. Hetastarch 0.7 (MW, 400 or 450 kDa).Each of the HES groups was compared to albumin,
crystalloids and gelatin.
Total blood loss
The total blood loss endpoint was defined as blood loss
from the start of the operation until 24 hours after sur-
gery. If data were not available for the complete time
frame, the largest available time span was selected for
analysis. In some studies, blood loss data were not avail-
able for the complete time interval, but were obtained
for several adjacent partial intervals. These intervals
were combined by adding the mean blood loss for each
of the partial intervals and by calculating the standard
deviation of the sum of these means, assuming a nega-
tive correlation of about 0.5 between the intervals. If cal-
culated blood loss was reported, we preferentially chose
this parameter because it is more accurate, as it accounts
for non-exteriorised blood losses.
Blood transfusions
The proportion of patients receiving blood transfusions
(packed red blood cells) intraoperatively and up to
24 hours after surgery was evaluated. Because the number
of patients receiving blood transfusions often was pre-
sented for separate time intervals, the total number of pa-
tients was estimated by determining the harmonic mean
of all possible outcomes rounded to the nearest integer.
The percentages of patients receiving blood transfusions
were used for calculation of the number of patients re-
ceiving blood transfusions rounded to the nearest inte-
ger. Publications that presented only the number of
patients receiving allogeneic blood products were in-
cluded in the meta-analysis using the number of pa-
tients who received any allogeneic blood product as a
substitute for the number of patients who received
packed red blood cells.
Volume infused
The endpoint “total combined volume of colloids and
crystalloids” was defined as the total amount of colloids
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ministered from the start of the operation until 24 hours
afterwards. If data were not available for the entire time
interval, the largest available interval was selected for
analysis. Volumes added via cardiopulmonary bypass
(CPB) were considered because they add to intraopera-
tive volume expansion. In some cases, volumes had to
be combined because different types of colloids and
crystalloids were infused or because fluid volumes were
presented not for the complete time interval, but for
several adjacent intervals. In these instances, fluid vol-
umes were combined by adding the mean volume for
each of the fluids in each of the intervals and calculating
the standard deviation of the sum of these means, as-
suming a negative correlation of 0.5 between the fluid
volumes in the partial intervals.
Length of stay in ICU and in hospital
“Length of stay in ICU” and “length of stay in hospital”
were defined as the number of days spent in the ICU or
hospital after the end of surgery. If data for length of
stay were not presented as mean ± standard deviation, it
was assumed that the distribution of data was symmet-
rical and approximately normal. Thus, median values
were used with the interquartile ranges divided by 1.35
as an estimate of standard deviation.
Acute kidney injury, mortality and need for reoperation
The number and proportion of patients who needed re-
operation were considered as mentioned by the study
authors, regardless of any specific time window. The
same approach was applied for AKI and mortality.
Statistical analysis
For effect size estimation for continuous endpoints, we
used standardised mean difference (SMD); for binary end-
points, we used risk ratios (RRs). Fixed-effects models
were applied to derive common point estimates and asso-
ciated 95% confidence intervals (CIs). The common effect
estimate was calculated as a weighted average of the ef-
fects estimated in the individual studies. For continuous
endpoints, the inverse-variance approach was used; for
binary endpoints, the Mantel-Haenszel approach was ap-
plied [10]. A zero-cell correction was performed for stud-
ies. If cells with the value 0 occurred, 0.5 was added to all
cells of the respective contingency table, except for cases
where no events were observed in both treatment groups.
A heterogeneity test was applied for each meta-analysis. In
case of significant results (P ≤0.05), possible causes were
analysed and discussed. In particular, if all study-specific
results pointed consistently in the same direction, valid in-
terpretation of the common effect estimate sometimes still
was possible. Statistical analyses were performed using theRevMan 5.2 software package (The Nordic Cochrane
Centre, Copenhagen, The Cochrane Collaboration, 2013).
Results
For overview of study selection, please refer to Figure 1.
The literature search yielded 2,100 hits, from among
which 288 were retrieved for detailed evaluation. Two
hundred thirty-seven of these studies were excluded for
the following reasons:
 Fifty-five were not prospective, randomised studies
in cardiac surgery patients published in the English
or German language.
 Fifty-two were not original research articles; that is,
they were abstracts, letters or comments.
 Thirty-three were published in languages other than
English or German.
 Seven did not have a full text available.
 Twenty-three were reviews or meta-analyses.
 Seventeen used no comparator or a comparator not
prespecified by us.
 Nineteen were duplicates or publications of the
same study providing no additional data.
 Twelve did not use HES as a study medication.
 Nine papers were retracted.
 Ten did not provide endpoints evaluated by our analysis.
Thus, we ultimately included in our meta-analysis 51
publications describing 49 clinical studies composed of
an aggregate of 3,439 patients. Of these 49 studies, 30
[11-42] were unblinded, 10 [43-52] were partly blinded
and 9 were completely blinded [53-61]. The duration of
follow-up covered a wide range, from 2 hours to 30 days.
Patients received on-pump coronary artery bypass graft-
ing in 25 studies, off-pump coronary artery bypass graft-
ing in 7 studies and mixed on-pump cardiac surgery in
15 studies. In four studies, the cardiac interventions per-
formed were not specified.
In two studies, the researchers reported additional
data about one of these trials. A total of 2,114 patients
were included in studies comparing tetrastarches to al-
bumin (n = 185), gelatin (n = 888), crystalloids (n = 679)
and other starches (n = 342). For pentastarches and
hetastarches, a total of 854 patients were included.
Because more than two substances were compared to
each other in some trials, the number of patients for sin-




Total blood loss was reported in 17 studies in which
starches were compared to albumin, 17 to crystalloids
and 14 to gelatin.
Figure 1 Overview of study selection.
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cations of the same study) seem to have mixed up the
results for HES treatment regimens. Therefore, it is not
clear which data are correct; we chose the more severe
blood loss of 895 ml for both starches in the meta-
analysis. Furthermore, Hanart et al. [43] reported total
blood loss in two ways; we used calculated blood loss.
For comparison of tetrastarch to albumin, three stud-
ies reported lower blood loss with tetrastarch (Figure 2)
(SMD, −0.34; 95% CI, −0.63, −0.05; P = 0.02). For crystal-
loids and gelatins, no significant difference compared to tet-
rastarches was found (tetrastarch vs. gelatin: SMD, −0.06;
95% CI −0.20, 0.08; p = 0.39; tetrastarch vs. crystalloids:
SMD, −0.05; 95% CI −0.20, 0.10; P = 0.54). In contrast, for
penta- or hetastarches, all analyses showed at least a trend
in favour of the comparator or even significantly larger
blood loss with the older starches (Additional files 2 and 3).
This difference between HES generations was also con-
firmed by studies comparing starches with each other
[27,30,46,54,55], with tetrastarch being associated with
significantly lower blood loss compared to pentastarch
(SMD, −0.33; 95% CI, −0.56, −0.11; P = 0.004) (Figure 3).
Significant heterogeneity amongst studies was found for
this comparison, but a sensitivity analysis excluding the
Muralidhar et al. [30] study confirmed the result for tetra-
starches (SMD, −0.26; 95% CI, −0.49, −0.03; P <0.05).
Need for transfusions
The need for transfusion was reported in nine studies
with HES vs. albumin, in eleven with HES vs. crystalloidsand in nine with HES vs. gelatin. No significant hetero-
geneity was found for these comparisons.
As for blood loss, Niemi et al. [32] and Schramko et
al. [35] (both publications of the same study) did not re-
port the same results for the HES treatment regimens.
Because the study medication was applied postopera-
tively and only the publication by Schramko et al. pre-
sents numbers of patients receiving transfusions after
surgery, only the data reported by Schramko et al. were
included in the meta-analysis. Patients receiving tetra-
starch 0.4 needed significantly less blood transfused for
cardiovascular surgery compared to patients receiving al-
bumin (RR, 0.70; 95% CI, 0.56; 0.89) (Figure 4).
No differences were found for tetrastarch compared to
crystalloids or gelatin (tetrastarch vs. gelatin: RR, 1.09;
95% CI, 0.91, 1.30; P = 0.34; tetrastarch vs. crystalloids:
RR, 1.19; 95% CI, 0.69, 2.03; P = 0.53) (Figure 4): For
crystalloids, only two of eight publications could be used
for meta-analysis of blood transfusion risk, and they
showed no significant difference in transfusion needs be-
tween both fluids (RR, 1.19; 95% CI, 0.69, 2.03; P = 0.53).
No transfusion events were reported in the remaining
six studies, but different data were reported about trans-
fusions. The mean volume of packed red blood cells was
lower for tetrastarch in one study [11], but not the num-
ber of patients who received them. In another study, the
mean number of packed red blood cells was lower with
tetrastarch [19]. In one study [42], the researchers re-
ported that equal volumes of red blood cells were re-
quired, without regard to whether volume expansion was
Figure 2 Blood loss with tetrastarch compared to albumin, gelatin or crystalloids. Units of blood loss were expressed in millilitres (ml),
except for Hanart et al. [43] and Van der Linden et al. [52], where the units were millilitres per kilogram body weight, and Lee et al. [47], where
no unit was indicated. The standardised mean difference (Std. mean difference) of the mean for the tetrastarch groups minus the mean for the
albumin (A), gelatin (B) and crystalloid (C) groups was used as effect size. Fixed-effects models were applied to calculate a common effect
estimate using the inverse-variance method (IV). SD, standard deviation; CI, Confidence interval.
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the investigators reported that more packed red blood
cells were transfused with tetrastarch [51,53].
For older starches, sparse data were available. Pentas-
tarch was associated with higher transfusion needs com-
pared to albumin (RR, 1.77; 95% CI, 1.12, 2.79; P = 0.01),
gelatin (RR, 2.86; 95% CI, 1.39, 5.88; P = 0.004) and crystal-
loids (RR, 1.35; 95% CI, 0.93, 1.97; P = 0.11) (Additionalfile 4), but the number of studies included in these com-
parisons was low.
In four studies, researchers reported higher transfusion
needs for hetastarch compared to albumin (RR, 1.48; 95%
CI, 1.04, 2.10; P = 0.03). In only two studies were data re-
ported related to blood transfusions with hetastarch com-
pared to crystalloids. There was no difference between the
two treatments, but available data were sparse [34,57].
Figure 3 Blood loss with tetrastarch compared to pentastarch. Units of blood loss were millilitres (ml). The standardised mean difference (Std.
mean difference) of the mean for the tetrastarch groups minus the mean for the pentastarch 0.5 group was used as effect size. A fixed-effects model
was applied to calculate a common effect estimate using the inverse-variance method (IV). SD, Standard deviation; CI, Confidence interval.
Figure 4 Transfusion requirements after tetrastarch compared to albumin, gelatin or crystalloids. The risk ratio was used as effect size
(transfusion risk for the hydroxyethyl starch groups divided by transfusion risk for the albumin (A), gelatin (B) and crystalloid (C) groups).
Fixed-effects models were applied to calculate a common effect estimate using the Mantel-Haenszel (M-H) approach. CI, confidence interval.
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Figure 5 Length of stay in the ICU or the hospital after tetrastarch compared to albumin, gelatin or crystalloids. The standardised mean
difference (Std. mean difference) of the mean for the hydroxyethyl starch groups minus the mean for the albumin (A), gelatin (B) and crystalloid
(C) groups was used as effect size. A fixed-effects model was applied to calculate a common effect estimate using the inverse-variance method
(IV). ICU, Intensive care unit; SD, Standard deviation; CI confidence interval.
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For the outcome parameters AKI, mortality and need for
reoperation, only very few events were reported: for ex-
ample, only 29 events for AKI in 1,538 cardiac surgical
patients for all HES cases. The overall incidence of mor-
tality was 5 deaths among 745 patients (0.7%) for all
HES cases and 8 deaths among 793 patients (1.0%) for
all comparators. Although there was no trend towards a
difference between starches and comparators, no reliable
analysis for separate HES generations compared to albu-
min, gelatin or crystalloids was possible. However, the
need for reoperations in a pooled analysis of each starch
generation compared to all comparators showed that it
was significantly greater with hetastarches (RR, 2.85;
95% CI, 1.27, 6.42; P = 0.01), whereas it did not differ
between tetrastarches (RR, 1.20; 95% CI, 0.39, 3.69;
P = 0.75) or pentastarches (RR, 1.64; 95% CI, 0.51, 5.24;
P = 0.41) and other volume replacements.
Length of stay in ICU and hospital
Compared to albumin, there was a trend towards longer
ICU and hospital lengths of stay for tetrastarches which
was not statistically significant (ICU: SMD, 0.39; 95%
CI, −0.04, 0.82; P = 0.08; hospital: SMD, 1.28; 95%
CI −0.20, 2.76; P = 0.09). In contrast, tetrastarch seemed
to have been associated with shorter ICU length of stay
and similar hospital length of stay compared to gelatin
(ICU: SMD, −0.10; 95% CI, −0.15, −0.05; P = 0.0002;
hospital: SMD, −0.15; 95% CI, −0.87, 0.52; P = 0.69).
Compared to crystalloids tetrastarches were associated
with significantly shorter lengths of stay in the ICU
(SMD, −0.06; 95% CI, −0.12, 0.00; P = 0.06) and in the
hospital (SMD, −0.52; 95% CI, −0.90, −0.14; P = 0.007)
(Figure 5). However, again, no definite conclusion is pos-
sible because of the low number of studies.
Similarly, for penta- and hetastarches, the number of
included studies is too low to allow definitive conclu-
sions. These comparisons can be found in Additional
files 5 and 6.
Efficacy evaluation
Volume infused
The need for fluids was assessed in 8, 12 and 14 studies
comparing HES to crystalloids, gelatin and albumin, re-
spectively. Our analysis shows no difference between tet-
rastarch and albumin (SMD, 0.06; 95% CI, −0.23, 0.35;
P = 0.67). Significant heterogeneity was indicated forthis comparison, most likely due to the low number of
studies. In contrast, a significantly lower volumetric
need was found when we compared tetrastarches to gel-
atin (SMD, −0.41; 95% CI, −0.58, −0.25; P <0.00001)
and crystalloids (SMD, −0.46; 95% CI, −0.77, −0.15;
P = 0.003) (Figure 6). Significant heterogeneity was also
found for these analyses. For tetrastarch vs. gelatin, the
study results reported by Muralidhar et al. [30] and
Alavi et al. [53] appear most relevant for heterogeneity,
but these results pointed in the same direction as those
from most other trials. Pentastarch 0.45 was as effective
as albumin (SMD, 0.18; 95% CI, −0.17, 0.54; P = 0.31)
and gelatin (SMD, −0.22; 95% CI, −0.53, 0.10; P = 0.18),
whereas pentastarch 0.5 was inferior to albumin (SMD,
0.57; 95% CI, 0.10, 1.04; P = 0.02) (Additional file 6).
For hetastarch, only sufficient data for a comparison to
albumin were available, indicating similar efficacy of
both fluids (SMD, 0.08; 95% CI, −0.13, 0.28; P = 0.47)
(Additional file 6).
Discussion
Our meta-analysis shows no evidence for a higher risk of
bleeding, blood transfusion or reoperation associated
with the third generation of HESs in patients undergoing
cardiac surgery. For blood loss and transfusion needs,
we found a trend amongst starches (that is, a reduction
of adverse effects) with third-generation starches. Tetra-
starch was superior to human albumin in terms of blood
loss and transfusion requirements. The efficacy of tetra-
starches, as judged by the amount needed for haemo-
dynamic stabilisation, was superior to crystalloids and
gelatin. Length of stay in the ICU or in the hospital
could be shorter with tetrastarches as compared to gela-
tins or crystalloids. In contrast, using starches with a
higher degree of molar substitution was associated with
adverse outcomes. Thus, our analysis indicates that the
development of newer-generation starches might have im-
proved the safety profile of HESs substantially over time.
Safety evaluation
Because of large volumes of priming solution and volume
replacement, blood loss and transfusion requirements are
especially relevant in cardiac surgery. A central safety as-
pect of starches is their effect on coagulation. Generations
with a higher degree of molar substitution (0.5 or higher)
have been shown to impair coagulation [62,63]. The re-
sults of several studies comparing tetrastarches with a
Figure 6 Efficacy of tetrastarch compared to albumin, gelatin or crystalloids as judged by total volume infusion. Units of total combined
volume of colloids and crystalloids were expressed in millilitres (ml), except for Hanart et al. [43] and Van der Linden et al. [38,52], where units
were expressed as millilitres per kilogram body weight (ml/kg). (A) Albumin. (B) Gelatin. (C) Crystalloid. The standardised mean difference (Std.
mean difference) of the mean for the hydroxyethyl starch group minus the mean for the albumin group was used as effect size. Fixed-effects
models were applied to calculate a common effect estimate using the inverse variance method (IV). SD, standard deviation; CI, confidence interval.
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smaller effect on coagulation with tetrastarches [1,64].
Our meta-analysis shows a reduction of blood loss and
need for transfusion with decreasing molar substitution
from heta- and penta- to tetrastarches. When we com-
pared blood loss and transfusion requirements with tetra-
starches, we found no significant difference compared to
crystalloids and gelatin. Furthermore, blood loss and
transfusion requirements with tetrastarches were signifi-
cantly lower compared to albumin. However, this result
was based on only 3 studies with 185 patients and thusshould be viewed as preliminary. In contrast, penta- and
hetastarches were inferior in terms of blood loss and
transfusion requirements when compared to other volume
replacements in our analysis.
Other safety parameters we analysed were overall mor-
tality, the incidence of AKI and the need for reopera-
tions, which might also indicate bleeding events. Firm
conclusions could not be drawn for AKI and mortality,
owing to a very low number of reported events. For
AKI, there is an overall trend towards providing specific
definitions only in the later studies, which mainly relied
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at least 50% above baseline) and need for renal replace-
ment therapy. In a recently published trial by Van der
Linden et al. [65], tetrastarch was compared with albu-
min in paediatric cardiac surgery. They assessed safety
parameters until 28 days after surgery and monitored
highly sensitive markers of renal function, but they could
not detect significant differences between groups. With
regard to the need for reoperations, a pooled analysis of
all starches showed no difference compared to other vol-
ume substitutes, which confirms the data about blood
loss and transfusions.
With regard to length of stay in the ICU or in the hos-
pital, tetrastarches seem to be superior to crystalloids
and gelatin. Albumin might offer advantages in terms of
length of stay compared to tetrastarches. As length of
stay in the hospital is a parameter that is especially
prone to non-medical confounders, such as availability
of secondary care or weekend discharges, the validity of
this endpoint may be lower than that for other safety
endpoints, given the low number of studies and patients
available for this comparison.
Efficacy evaluation
Generally, volume used for fluid therapy is a tricky par-
ameter in assessment of the efficacy of therapy, as this
need is judged by physicians on the basis of different pa-
rameters, such as volumetric parameters or cardiac pre-
load. Yet, it is the only parameter consistently reported
in studies on volume therapy. In addition, combining
study results might be more reliable than evaluating sin-
gle studies, as individual deviations in judgement about
the need for fluid therapy might regress towards the
mean. The volume effect of colloids has been discussed
extensively and also controversially [66,67]. Our analysis
of the total amount of fluid replacement drugs per case
indicates that volume therapy with tetrastarches required
significantly less volume than with crystalloids. Com-
pared to gelatin, tetrastarch use also led to the infusion
of significantly lesser total amounts, supporting the
notion that they might have a greater volume effect
[68,69]. However, significant heterogeneity was found
amongst the study populations. Therefore, this result
needs further confirmation. More studies would be ne-
cessary to explore potential sources of heterogeneity.
Compared to human albumin, second-generation HES
with a molar substitution of 0.5 (pentastarches) seem to
be less efficient, which was not the case for tetrastarches.
This finding is consistent with previous studies in which
researchers reported similar volumetric effects for albu-
min and tetrastarches [68-71]. However, to draw reliable
conclusions about intravascular volumetric effects from
total infused amounts over time guided by often insuffi-
cient routine surrogates (for example, blood pressure,heart rate) is problematic. Beyond that, significant het-
erogeneity was found amongst the study populations.
Therefore, this result needs to be confirmed. More stud-
ies using adequate targets of fluid therapy would be ne-
cessary to explore and exclude potential sources of
heterogeneity and to focus on what we actually want to
know when talking about intravascular persistence.
Limitations
Dosing of colloids was markedly different amongst stud-
ies, which were conducted worldwide, possibly resulting
in different treatment regimens that might result in rele-
vant heterogeneity. This might affect the results, espe-
cially owing to the low number of studies for some of
the comparisons. However, it increases the external val-
idity of our findings. Publication bias existed, as de-
scribed previously [5]. For comparison of efficacy, no
data from extended monitoring devices were available
beyond the weak surrogate parameter of the volume of
infused fluids.
Borderline sufficient data were available for some of
our analyses. Also, statistical significance for our com-
parisons does not automatically imply clinical relevance.
However, there is an overall trend that starches have
been improved over time with tetrastarches providing
the most reliable data.
Conclusions
Recent studies in septic patients suggest that adverse ef-
fects of HESs might outweigh the benefits in these pa-
tients [72,73]. On the other hand, it has to be taken into
account that the pathophysiology of these patients dif-
fers fundamentally from surgical patient populations not
primarily presenting with a capillary leak negatively af-
fecting colloidal intravascular persistence [74]. As the
safety debate for surgical patients is ongoing, an evalu-
ation of HESs for specific patient populations seems to
be mandatory.
We conclude that tetrastarches are improved com-
pared to older starches in regards to blood loss or need
for transfusions. On the basis of the available data, tetra-
starches seem to be efficient and safe volume substitutes
which can be recommended for cardiac surgery.
Key messages
 Tetrastarches are improved in regards to blood loss
or need for transfusions compared to older starches.
 We found no safety issues with tetrastarches in
terms of blood loss, transfusion requirements or
hospital length of stay in cardiac surgery.
 Volume therapy with tetrastarches required
significantly less volume than with crystalloids
and gelatin.
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Additional file 1: Target terms for literature search.
Additional file 2: Blood loss with pentastarch compared to
albumin, gelatin or crystalloids. Units of blood loss were millilitres (ml),
except for Van der Linden et al. [52], where units were millilitres per
kilogram body weight. The standardized mean difference of the mean for
the pentastarch groups minus the mean for the albumin, gelatin and
crystalloid groups was used as effect size. Fixed-effect models were
applied to calculate a common effect estimate using the inverse
variance method. Tigchelaar et al. [37] only report mean blood loss
without presenting standard deviation (indicated by a ‘0’ in this figure).
SD, Standard deviation; Std. mean difference, Standardized mean
difference; IV, Inverse variance method; CI, Confidence interval.
Additional file 3: Blood loss with hetastarch compared to albumin
or crystalloids. Units of blood loss were millilitres (ml), except for
Brutocao et al. [14], where units were millilitres per kilogram body weight
(ml/kg), and Palanzo et al. [41], where no unit was indicated. The
standardized mean difference of the mean for the hetastarch groups
minus the mean for the albumin and crystalloid groups was used as
effect size. Fixed-effects models were applied to calculate a common
effect estimate using the inverse variance method. SD, Standard
deviation; Std. mean difference, Standardized mean difference; IV, Inverse
variance method; CI, Confidence interval.
Additional file 4: Transfusion requirements after penta- or hetastarch
compared to albumin, gelatin, or crystalloids. The risk ratio was used as
effect size (transfusion risk for the penta- or hetastarch groups divided by
transfusion risk for the albumin, gelatin and crystalloid groups). Fixed
effect models were applied to calculate a common effect estimate using
the Mantel-Haenszel approach. M-H, Mantel-Haenszel approach; CI,
Confidence interval.
Additional file 5: Length of stay in ICU or hospital after pentastarches
compared to albumin and crystalloids. The standardized mean difference
of the mean for the pentastarch group minus the mean for the albumin
group was used as effect size. A fixed-effects model was applied to calculate
a common effect estimate using the inverse variance method. SD, Standard
deviation; Std. mean difference, Standardized mean difference; IV, Inverse
variance method; CI, Confidence interval.
Additional file 6: Length of stay in ICU or hospital after hetastarches
compared to albumin and crystalloids. The standardized mean difference
of the mean for the pentastarch group minus the mean for the albumin
group was used as effect size. A fixed-effect model was applied to calculate
a common effect estimate using the inverse variance method. SD, Standard
deviation; Std. mean difference, Standardized mean difference; IV, Inverse
variance method; CI, Confidence interval.Abbreviations
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